Your browser doesn't support javascript.
loading
Indirect benefits are a crucial consideration when evaluating SARS-CoV-2 vaccine candidates.
Gallagher, Molly E; Sieben, Andrew J; Nelson, Kristin N; Kraay, Alicia N M; Orenstein, Walter A; Lopman, Ben; Handel, Andreas; Koelle, Katia.
Afiliación
  • Gallagher ME; Department of Biology, Emory University, Atlanta, GA, USA. mgallagher@emory.edu.
  • Sieben AJ; School of Medicine, Emory University, Atlanta, GA, USA.
  • Nelson KN; Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA.
  • Kraay ANM; Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA.
  • Orenstein WA; Emory Vaccine Center, School of Medicine, Emory University, Atlanta, GA, USA.
  • Lopman B; Emory-UGA Center of Excellence of Influenza Research and Surveillance, Atlanta, GA, USA.
  • Handel A; Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA.
  • Koelle K; Department of Epidemiology and Biostatistics, College of Public Health, University of Georgia, Athens, GA, USA.
Nat Med ; 27(1): 4-5, 2021 01.
Article en En | MEDLINE | ID: mdl-33230343
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Vacunas contra la COVID-19 / SARS-CoV-2 / COVID-19 Límite: Humans Idioma: En Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Vacunas contra la COVID-19 / SARS-CoV-2 / COVID-19 Límite: Humans Idioma: En Año: 2021 Tipo del documento: Article